Physician profile

Jonathan C Ellis

Gastroenterology (Internal Medicine) · Beverly Hills, CA

NPI 1306876263

$13,290.03

in general payments reported to CMS, 2019-2025

43 companies · $223 in 2025

The $223 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,012.07
Education$46.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $3,523.64 2019-2025 Xifaxan, Trulance, Plenvu
Abbvie INC. $2,212.17 2019-2024
Janssen Biotech, INC. $1,085.31 2019-2024 Stelara
Takeda Pharmaceuticals U.S.A., INC. $952.05 2019-2025 Entyvio, Gattex
Qol Medical, LLC $597.94 2019-2025 Sucraid, Sucraid
Ferring Pharmaceuticals INC. $582.34 2019-2022
Shire North American Group INC $500.00 2019
Redhill Biopharma INC. $401.98 2021-2024 Talicia, Movantik, Aemcolo
Nestle Healthcare Nutrition INC. $353.18 2020-2023
Ardelyx, INC. $325.47 2022-2023 Ibsrela
Merck Sharp & Dohme LLC $317.38 2019-2024 Dificid
Celgene Corporation $302.60 2021-2024 Zeposia
Ironwood Pharmaceuticals, INC $224.31 2021-2024 Linzess
Intercept Pharmaceuticals, INC. $177.36 2019-2025
Genzyme Corporation $168.93 2022-2024
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Biohaven Pharmaceuticals, INC. $156.44 2021
Daiichi Sankyo INC. $142.53 2019-2021
Lundbeck LLC $126.05 2021-2023 Vyepti
Pfizer INC. $112.86 2023-2024
E.R. Squibb & Sons, L.L.C. $104.82 2022
Nevro Corp. $101.55 2021-2024 Senza
Amgen INC. $94.66 2021-2022
Alnylam Pharmaceuticals INC. $80.33 2022-2024 Givlaari
Merz Pharmaceuticals, LLC $75.11 2021-2022
Regeneron Healthcare Solutions, INC. $61.31 2022
Boston Scientific Corporation $59.90 2022-2023 Superion Indirect Decompression System
Teva Pharmaceuticals USA, INC. $57.54 2022-2023 Ajovy
Concordia Pharmaceuticals INC. $46.13 2019
Perspectum Diagnostics LTD $43.01 2022
Impel Pharmaceuticals INC. $36.32 2023 Trudhesa
Mallinckrodt Hospital Products INC. $30.53 2024 Terlivaz
Allergan, INC. $29.66 2019
Aimmune Therapeutics, INC. $29.25 2024
Braintree Laboratories, INC. $25.11 2019
Ethicon US, LLC $24.05 2022
Novo Nordisk INC $21.20 2023 Ozempic, Rybelsus
Exact Sciences Corporation $19.20 2023 Cologuard Collection Kit
Spr Therapeutics, INC $17.49 2022
Alfasigma USA, INC. $17.27 2021
Almatica Pharma LLC $15.61 2021
Upsher-Smith Laboratories LLC $12.60 2021
Vivus LLC $12.50 2019
Astrazeneca Pharmaceuticals LP $12.34 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jonathan C Ellis

$13,290.03

in general payments reported 2019-2025

Years
2019-2025
Top company
Salix Pharmaceuticals, A Division of Bausch Health US, LLC
Context
The $223 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).

https://glasscript.com/doctor/331210/jonathan-c-ellis

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.